Table 2.
Symptoms experienced by the study cohort following natural infection, 1st dose of vaccine, and 2nd dose of vaccine.
| Natural Infection (NI)b | Natural Infection + Vaccine Dose 1 (NI + D1) | Natural Infection + Vaccine Dose 2 (NI + D2) | |
|---|---|---|---|
| Symptoms Reported During SARS-CoV-2 Infection a | |||
| Asymptomatic | 10 (20%) | – | – |
| Anosmia | 27 (55%) | – | – |
| Congestion/rhinorrhea | 26 (53%) | – | – |
| Cough | 23 (47%) | – | – |
| Difficulty breathing | 12 (24%) | – | – |
| Dysgeusia | 26 (53%) | – | – |
| Fatigue | 31 (63%) | – | – |
| Fever | 18 (37%) | – | – |
| Myalgias | 28 (57%) | – | – |
| Nausea or vomiting | 5 (10%) | – | – |
| Sore Throat | 15 (31%) | – | – |
| Upset Stomach | 14 (29%) | – | – |
| Local Symptoms Reported Following Vaccination a | |||
| Injection site pain | – | 25 (51%) | 26 (53%) |
| Injection site redness | – | 2 (4%) | 4 (8%) |
| Injection site swelling | – | 4 (8%) | 5 (10%) |
| Systemic Symptoms Reported Following Vaccination a | |||
| Asymptomatic | – | 22 (45%) | 20 (41%) |
| Chills | – | 9 (18%) | 11 (22%) |
| Fatigue | – | 14 (29%) | 19 (39%) |
| Fever | – | 10 (20%) | 10 (20%) |
| Headache | – | 14 (29%) | 12 (24%) |
| Myalgias/Muscle Aches | – | 12 (24%) | 14 (29%) |
Each count is the number of individuals who self-reported each symptom at the timepoint listed in each column. Percentages are based on the total n for each column.
a
All symptoms reported during SARS-CoV-2 Infection, as well as local and systemic symptoms following vaccination were included in LASSO modeling as shown in Supplementary Table 1 .
b
All samples collected following natural infection were included for analysis.